JAN 15, 7:23 PM EST
`
`World
`
`U.S.
`
`Economy & Markets
`
`Companies
`
`Technology
`
`Digital Life
`
`Culture
`
`Sports
`
`Crypto
`
`Opinion
`
`US Edition
`
`NEWSLETTER SIGNUP
`
`BUSINESS
`11 Blockbuster 'Drugs To Watch' In 2015
`
`By Amy Nordrum
`
`03/24/15 AT 11:38 AM EDT
`
`  
`
` 
`
`Sales of 11 blockbuster drugs set to pull in more than $1 billion in revenue by 2019 will begin this year. A new list of the pharmaceutical industry's most lucrative drugs
`represents a signicant boost in the market, up from only three medicines of blockbuster status that debuted in 2014.
`(PHOTO: PIXABAY)
`
`Eleven blockbuster drugs will debut on the pharmaceutical market this year, and each is expected to pull in at least $1 billion in
`revenue within ve years of launch, according to Thomson Reuters’ annual “Drugs to Watch” report. The drugs represent some of
`the most lucrative opportunities during the coming years for 10 companies with candidates on the list, including Novartis, Pzer
`and Sano.
`
`Overall, the number of high-revenue drugs slated to begin sales this year is up dramatically from only three blockbusters that
`arrived on the market last year. Richard Harrison, scientic director at Thomson Reuters, says the rise is a good indicator of the
`health of the industry and the FDA’s eorts to more quickly move some drugs from research through clinical trials.
`
`ADVERTISEMENT
`
`Novo Nordisk Exhibit 2479
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`

`

`-50%
`
`Bristol-Myers Squibb has the most highly valued drug with Opdivo, a medicine to treat melanoma. The drug is projected to bring in
`$5.7 billion by 2019, according to analysts at Thomson Reuters who used the company's Cortellis Competitive Intelligence tool to
`evaluate the pipelines of pharmaceutical companies. Harrison says Opdivo will likely receive approval to expand treatment beyond
`the limited number of patients for which it is currently approved, which could further add to its value.
`
`Another blockbuster on the list is Ibrance, Pzer’s new drug for women with breast cancer that has spread throughout their bodies
`and failed to respond to other treatments. Ibrance was approved through the FDA’s fast-track process for new cancer drugs earlier
`this year. Several of the most promising drugs featured in the compilation target slivers of patient populations that share a
`particular form of a disease, such as a cystic brosis drug by Vertex Pharmaceuticals that treats a specic genetic mutation.
`
`Lower Blood Sugar Levels - Order
`Now and Get 66% Off!
`www.researchverified.com
`
`Developing specialty treatments for a narrow population of patients with a given disease has been a growing trend within the
`industry. Small patient populations are often lucrative because insurance companies are relatively willing to pay high costs for
`treatment of a small group if there is no other option available, whereas they may balk at the price if a drug was needed for a greater
`number of people. “There's two ways to make a lot of money on drugs -- one is that the drug could treat a large number of people,
`and the other is that it could be very high-priced,” Harrison says.
`
`Below is the full list of the industry’s most lucrative drugs, including their comapny names and 20149 sales forecasts as laid out in
`Thomson Reuters’ annual “Drugs to Watch” report:
`
`Read This Before You Buy - Official
`ResearchVerified®
`www.researchverified.com
`
`1. Opdivo, Bristol-Myers Squibb, $5.684 billion
`
`2. Praluent, Regeneron Pharmaceuticals and Sano, $4.414 billion
`
`3. LCZ-696, Novartis, $3.731 billion
`
`4. Ibrance, Pzer, $2.756 billion
`
`5. Iumacaftor plus ivacaftor, Vertex Pharmaceuticals, $2.737 billion
`
`6. Viekira Pak, AbbieVie, $2.500 billion
`
`7. Evolocumab, Amgen and Astellas Pharma, $1.862 billion
`
`8. Gardasil 9, Merck & Co., $1.637 billion
`
`9. Brexpiprazole, Ostuka Pharmaceutical and Lundbeck, $1.353 billion
`
`10. Toujeo, Sano, $1.265 billion
`
`11. Cosentyx, Novartis, $1.082 billion
`
`RELATED STORIES
`
`Pfizer To Acquire Hospira, Maker of Injectables and Biosimilars, For $17 Billion
`Bristol-Myers Squibb Co (BMY) Expands Cancer Treatment Pipeline With $1.25 Billion Purchase Of Flexus Biosciences
`
`IBT Fast Start - Let the best of International News come to you
`Sign up and stay up to date with our daily newsletter.
`
`Enter your email.
`
`SIGN UP NOW
`
`Novo Nordisk Exhibit 2479
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`